Association of Non-LDL Indices with Recurrent Stroke Risk while on Lipid-Modifying Therapy
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Park, Jong-Ho | - |
dc.contributor.author | Ovbiagele, Bruce | - |
dc.date.accessioned | 2022-07-08T20:18:22Z | - |
dc.date.available | 2022-07-08T20:18:22Z | - |
dc.date.created | 2021-05-12 | - |
dc.date.issued | 2020 | - |
dc.identifier.issn | 1340-3478 | - |
dc.identifier.uri | https://scholarworks.bwise.kr/hanyang/handle/2021.sw.hanyang/146500 | - |
dc.description.abstract | Aims: Low-density lipoprotein (LDL)-lowering statin therapy is an established secondary stroke prevention strategy. However, the differential impact of key non-LDL levels on recurrent stroke risk, while on lipid-modifying therapy (LT), remains unclear. Methods: We analyzed the dataset of a multicenter trial involving 3640 recent (<4 months) noncardioembolic stroke patients followed for 2 years. Participants were categorized into four groups of presumed improving lipid profile: level 0, no LT prescribed; level I, LT use with low high-density lipoprotein cholesterol (HDL-C) (<40 mg/dL for men; <50 mg/dL for women); level II, LT use with high HDL-C (≥ 40 mg/dL and ≥ 50 mg/dL, respectively); and level III, level II with low triglycerides (<150 mg/dL). Independent associations of LT category with stroke, major vascular events (MVEs; stroke/coronary heart disease/vascular death), and all-cause death were assessed. Results: LTs were mostly statins (>95%). The unadjusted recurrent stroke rate declined with LT category level (9.2% for level 0; 8.4% for level I; 7.5% for level II; and 5.7% for level III). Compared with level 0, the adjusted hazard ratio of stroke for level I was 0.78 (95% confidence interval (CI), 0.59–1.03), level II 0.80 (0.54–1.18), and level III 0.63 (0.43–0.91). Multivariable analyses of MVEs and all-cause death followed a similar pattern of declining risk with higher LT category level. Conclusions: Compared with the nonuse of LT, there may be a hierarchy of residual vascular risk after stroke by non-LDL type and target, while on LT. Particularly, stroke patients with low HDL-C levels on LT may benefit from additional therapeutic strategies to improve their outcomes. | - |
dc.language | 영어 | - |
dc.language.iso | en | - |
dc.publisher | JAPAN ATHEROSCLEROSIS SOC | - |
dc.title | Association of Non-LDL Indices with Recurrent Stroke Risk while on Lipid-Modifying Therapy | - |
dc.type | Article | - |
dc.contributor.affiliatedAuthor | Park, Jong-Ho | - |
dc.identifier.doi | 10.5551/jat.49304 | - |
dc.identifier.scopusid | 2-s2.0-85078868039 | - |
dc.identifier.wosid | 000512302000005 | - |
dc.identifier.bibliographicCitation | JOURNAL OF ATHEROSCLEROSIS AND THROMBOSIS, v.27, no.2, pp.144 - 154 | - |
dc.relation.isPartOf | JOURNAL OF ATHEROSCLEROSIS AND THROMBOSIS | - |
dc.citation.title | JOURNAL OF ATHEROSCLEROSIS AND THROMBOSIS | - |
dc.citation.volume | 27 | - |
dc.citation.number | 2 | - |
dc.citation.startPage | 144 | - |
dc.citation.endPage | 154 | - |
dc.type.rims | ART | - |
dc.type.docType | Article | - |
dc.description.journalClass | 1 | - |
dc.description.isOpenAccess | Y | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.relation.journalResearchArea | Cardiovascular System & Cardiology | - |
dc.relation.journalWebOfScienceCategory | Peripheral Vascular Disease | - |
dc.subject.keywordPlus | DENSITY-LIPOPROTEIN CHOLESTEROL | - |
dc.subject.keywordPlus | ISCHEMIC-STROKE | - |
dc.subject.keywordPlus | ATHEROGENIC DYSLIPIDEMIA | - |
dc.subject.keywordPlus | MYOCARDIAL-INFARCTION | - |
dc.subject.keywordPlus | METABOLIC SYNDROME | - |
dc.subject.keywordPlus | PREVENTION | - |
dc.subject.keywordPlus | MANAGEMENT | - |
dc.subject.keywordPlus | DIAGNOSIS | - |
dc.subject.keywordPlus | HDL | - |
dc.subject.keywordAuthor | Lipid | - |
dc.subject.keywordAuthor | Statin | - |
dc.subject.keywordAuthor | Stroke | - |
dc.subject.keywordAuthor | HDL | - |
dc.subject.keywordAuthor | Triglycerides | - |
dc.subject.keywordAuthor | Dyslipidemia | - |
dc.identifier.url | https://www.jstage.jst.go.jp/article/jat/27/2/27_49304/_article | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
222, Wangsimni-ro, Seongdong-gu, Seoul, 04763, Korea+82-2-2220-1365
COPYRIGHT © 2021 HANYANG UNIVERSITY.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.